CGTLive’s Weekly Rewind – August 5, 2022
Review top news and interview highlights from the week ending August 5, 2022.
Welcome to CGTLive’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.
1. Allogeneic Cell Therapy Trial to Initiate in Ovarian Cancer
Avenge Bio previously presented positive preclinical data at the ASGCT 2022 meeting.
2. Craig M. McDonald, MD, on Safety and Efficacy of DMD Cell Therapy
The principal investigator of the HOPE-2 trial discussed safety and efficacy of Capricor’s CAP-1002.
3. REGENXBIO's MPSII Gene Therapy Charts Course to Approval
The FDA will consider RGX-121's BLA in an accelerated approval pathway.
4. IND Cleared for Dual-Targeted CAR T Therapy for B-Cell Malignancies
UCART2022 is an allogeneic therapy that targets both CD20 and CD22.
5. IND Halted for T-Cell Malignancy Multiplex-Edited Cell Therapy
Beam Therapeutics submitted an IND for BEAM-201 in June 2022.
Newsletter
Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.
Jeffrey Chamberlain, PhD, on the Import of Early Intervention in DMD
July 10th 2025The McCaw Endowed Chair of Muscular Dystrophy at University of Washington, discussed how comprehensive care for DMD patients involves early diagnosis, steroid treatment, consideration of mutation-specific therapies, and more.
